ResearcherNational Cancer InstituteNo recent work listed

Cara M. Kenney

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5012311589. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper

Papers 1

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s10637-020-01044-8 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Niharika B. Mettu · 1 shared paper, 2021 · strength 0.13
- Paper Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic duct… DOI 10.1007/s10637-020-01044-8 ↗
Edward Jae-Hoon Kim · 1 shared paper, 2021 · strength 0.13
- Paper Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic duct… DOI 10.1007/s10637-020-01044-8 ↗
Udo Rudloff · 1 shared paper, 2021 · strength 0.13
- Paper Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS G12R-mutant pancreatic duct… DOI 10.1007/s10637-020-01044-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.